{"nctId":"NCT04688346","briefTitle":"Cardiovascular Effects of Racemic Epinephrine Pellets","startDateStruct":{"date":"2019-06-10","type":"ACTUAL"},"conditions":["Epinephrine Causing Adverse Effects in Therapeutic Use"],"count":13,"armGroups":[{"label":"Control","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: HemeRX epinephrine pellets"]},{"label":"Intervention","type":"EXPERIMENTAL","interventionNames":["Drug: HemeRX epinephrine pellets"]}],"interventions":[{"name":"HemeRX epinephrine pellets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Children ages 2-9 years undergoing general anesthesia for comprehensive dental treatment at the University of Washington Center of Pediatric Dentistry.\n2. Healthy patients according to the American Society of Anesthesiologists (ASA) classification I or II.\n3. Patients who have caries lesions requiring prefabricated crowns on primary maxillary first molars #B and #I.\n\nExclusion Criteria:\n\n1. Pediatric patients with any severe systemic illness (ASA Classification III or greater).\n2. Pediatric patients with known cardiac arrhythmia, cardiovascular disease, diabetes and thyroid disease.\n3. Patients who are taking anti-arrhythmic, antihypertensive, or ionotropic medications.\n4. Patients who would need pulpotomy or pulpectomy treatment on primary maxillary first molars #B and I.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Years","maximumAge":"9 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cardiovascular Outcomes","description":"To determine heart rate change of patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.5","spread":"18.2"},{"groupId":"OG001","value":"93.4","spread":"15.1"}]}]}]},{"type":"PRIMARY","title":"Cardiovascular Outcomes","description":"To determine blood pressure change of patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"5.1"},{"groupId":"OG001","value":"-2.7","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Hemostasis Efficacy","description":"To determine time to achieving hemostasis (based upon subjective assessment of surgeon) on patients receiving treatment with topical racemic epinephrine compared to those receiving a placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"2"},{"groupId":"OG001","value":"2.2","spread":"2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":[]}}}